UroGen Pharma Ltd. Adjustments to Additional Paid in Capital, Warrant Issued
UroGen Pharma Ltd. (URGN) reported Adjustments to Additional Paid in Capital, Warrant Issued of $18.64 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-03-02
- UroGen Pharma Ltd. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $0.00.
- UroGen Pharma Ltd. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-06-30 was $18.64M.
- UroGen Pharma Ltd. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-12-31 was $0.00.
- UroGen Pharma Ltd. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $18.64M, a 61.72% decline from fiscal 2023.
- UroGen Pharma Ltd. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $48.70M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $18.64M derived: sum of 3 quarters · filed 2026-03-02 | $18.64M 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.64M derived: sum of 2 quarters · filed 2025-11-06 | $18.64M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $18.64M 10-Q · filed 2025-08-07 | $18.64M 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $48.70M derived: sum of 2 quarters · filed 2025-03-10 | $48.70M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $48.70M 10-Q · filed 2024-11-06 | $48.70M 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |